| CAS NO: | 1228108-65-3 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 2mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Molecular Weight (MW) | 700.78 |
|---|---|
| Formula | C42H40N2O8 |
| CAS No. | 1228108-65-3 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 100 mg/mL (142.7 mM) |
| Water: <1 mg/mL (slightly soluble or insoluble) | |
| Ethanol: 54 mg/mL (77 mM) | |
| Synonyms | BI-97C1; BI 97C1; BI97C1 |
| General | BI-97C1 displays in vivo efficacy in transgenic mice in which Bcl-2 is overexpressed in splenic B-cells and also demonstrates superior single-agent antitumor efficacy in a prostate cancer mouse xenograft model that depends on Mcl-1 for survival |
|---|---|
| Animal model | Bcl-2 transgenic mice, human prostate cancer xenografts |
| Formulation | Ethanol:Cremophor EL:saline = 10:10:80 |
| Dosages | 1 , 3, 5 mg/kg |
| Administration | intraperitoneally |
| Reference | [1] Wei J, et al. J Med Chem, 2010, 53(10), 4166-4176 |
 The combination regimen of Sabutoclax and Celecoxib inhibits OSCC tumor growth in athymic nude mice. Oncotarget 6(18):16623-37, 2015 |  Genetic or pharmacological knockdown of Mcl-1 sensitizes PC to mda-7/IL-24–mediated apoptosis. PNAS, 108 (21), 8785–8790, 2011 |
m.cnreagent.com